Melanocortin receptor

A single amino acid in MC1R's transmembrane domain 3 is key for Melanotan-like peptide selectivity, enabling receptor-specific agonism.

This research provides a precise molecular blueprint for designing next-generation melanocortin peptides with high receptor selectivity. For peptide users and developers, this means that compounds could be engineered …

Melanotan-II in the lateral hypothalamus blunted binge-like ethanol consumption in C57BL/6J mice

This research provides strong evidence that the melanocortin system, particularly within the lateral hypothalamus, is a key modulator of binge drinking. For biohackers or researchers experimenting with melanocortin ag…

Melanotan-II Increases Sympathetic Nerve Activity in Rats, but Only When NPY Y1 Receptors are Blocked

This research clarifies a key mechanism for both leptin and melanocortin signaling in the central nervous system's control of cardiovascular function. For researchers and biohackers using peptides like Melanotan-II, i…

Melanotan II (MTII) analog alleviates Alzheimer's pathology in mice by reducing amyloid-beta, neuroinflammation, and reactive astrocytes.

These findings highlight the melanocortin system as a promising therapeutic target for Alzheimer's disease, moving beyond symptomatic treatment to address core pathologies like amyloid burden and neuroinflammation. Fo…

alpha-MSH and KPV suppress inflammation and induce antigen-specific tolerance via MC-1R

**alpha-MSH and KPV represent a dual-action immunotherapeutic strategy**: simultaneously suppressing pro-inflammatory cytokine cascades and actively inducing antigen-specific tolerance via CTLA4(+)/IL-10(+) T cells — …

KPV and alpha-MSH Elevate Intracellular Calcium in Keratinocytes via MC-1R, Not Cyclic AMP

**The assumed requirement for cyclic AMP in KPV and alpha-MSH anti-inflammatory action must be reconsidered** — at least in keratinocytes, the operative second messenger appears to be intracellular calcium, not cAMP. …

KPV and alpha-MSH suppress inflammation via NF-kappaB, cytokines, and adhesion pathways

**KPV and K(D)PT represent a structurally minimal, pharmacologically potent anti-inflammatory scaffold** that could be developed into topical, ophthalmic, or oral formulations for inflammatory skin, eye, and bowel dis…

KPV tripeptide reduces colitis severity and rescues mice from DSS-induced death

**KPV's efficacy in two mechanistically distinct colitis models, including survival rescue in MC1R-null animals, meaningfully broadens its therapeutic relevance** beyond a single signaling pathway — a common liability…

Melanocortin Peptides: From Discovery to Clinical Therapies for Skin and Sexual Function

This research highlights the significant therapeutic potential of melanocortin peptides in addressing unmet medical needs. The development of MTI could offer a novel, preventative approach to skin cancer through induc…

Preclinical Insights into Bremelanotide's Brain Mechanisms for Boosting Female Sexual Function